Streptococcal preparation (OK-432) enhances monoclonal antibody NCC-ST-421 cytotoxicity against human colon cancer

Anticancer Research

Volumn 17, Issue 4 A, 1997, Pages 2449-2453

  Kawano, Y ^a   Watanabe, Masahiko ^a   Kubota, T ^a   Nishibori, H ^a   Kurihara, N ^a   Teramoto, T ^a   Kitajima, M ^a  

^a KEIO UNIVERSITY   (Japan)

Author keywords

Antibody dependent cellular cytotoxicity (ADCC); Colon cancer; Immunotherapy; Monoclonal antibody; OK 432 (streptococcal preparation)

Indexed keywords

ANTINEOPLASTIC AGENT; COMPLEMENT; IMMUNOGLOBULIN G3; MONOCLONAL ANTIBODY; PICIBANIL;

ANTIGEN ANTIBODY REACTION; ARTICLE; CANCER CELL; CELL MEDIATED CYTOTOXICITY; COLON CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DIGESTIVE SYSTEM CANCER; HUMAN; HUMAN CELL; IMMUNOTHERAPY; LYMPHOCYTE; PRIORITY JOURNAL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, NEOPLASM; DRUG SYNERGISM; HUMANS; IMMUNOTHERAPY; MACROPHAGES, PERITONEAL; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; PICIBANIL; TUMOR CELLS, CULTURED;

EID: 0030857223     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Dillman RO: Antibody as cytotoxic therapy. J Clin Oncol 12: 1497-1515, 1994.
2. Houghton AN, Mintzer D, Cordon-Cardo C, Welt SW, Fliegel B, Vadhan S, Carswell E, Melamed MR, Oettgen HF, Old LJ: Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: a phase I trial in patients with malignant melanoma. Proc Natl Acad Sci USA 82: 1242-1246, 1985.
3. Riethmuller G, Schneider-Gadicke E: Randomized trial of monoclonal antibody for adjuvant therapy of lesected Dukes' C colorectal carcinoma. Lancet 343: 1177-1188, 1994.
4. Sears HF, Herlyn D, Steprewski Z, Koprowski H: Phase II clinical trial of a murine monoclonal antibody cytotoxic for gastrointestinal adenocarcinoma. Cancer Res 45: 5910-5913, 1985.
5. DeLey M, Claeys H: Streptococcal preparation OK-432 induced interferon in human leukocytes: purification and characterization. Int Arch Allergy Appl Immunol 74: 21-28, 1984.
6. Saito M, Nanjo M, Kataoka M: Adoptive immunotherapy by pantropic killer cells recovered from OK432-induced tumor sites in mice. Cancer Res 48: 4163-4167, 1988.
7. Uchida A, Yanagawa E, Mickshe M: In vivo and in vitro augmentation of natural killing and auto-tumor killing activity by OK-432. Excerpta Medica 140: 2621-2624, 1980
8. Torisu M, Katano M: New approach to management of malignant ascites with Streptococcal preparation, OK-432 I. Improvement of host immunity and prolongation of survival. Surgery 93: 365-373, 1983.
9. Watanabe M, Hirohashi S, Shimosato Y, Ino Y, Yamada T, Teshima S, Sekine T, Abe O: Carbohydrate antigen defined by monoclonal antibody raised against gastric cancerxenograft. Jpn J Cancer Res 76: 43-52, 1985.
10. a (m4V4Fuc2Lc6) as human tumor-associated antigen. J Biol Chem 266: 8439-8446, 1991.
11. a) epitope. CancerRes 51: 2199-2204, 1991.
12. Reali E, Guiliali AL, Spisani S, Moretti S, Trniell S: Interferon-γ enhances monoclonal antibody 17-1A-dependentneutrophil cytotoxicity toward colorectal carcinoma cell line SW11-16. Clin Immunol Immunother 71: 105-112, 1994.
13. Ragnhammar P, Magnusson I, Masucci G, Mellstedt H: Thetherapeutic use of the unconjugated monoclonal antibodies (MAb) 17-1A in combination with GM-CSF in the treatment of colorectal carcinoma(CRC). Med Oncol Tumor Pharmacother 10: 61-70, 1993.
14. a) mediated by monoclonal antibody NCC-ST-421 in adoptive immunization using SCID mice. Cancer Immunol Immunother 37: 245-250, 1993.
15. Pross HF, Baines MG, Runbin P, Shatagge P, Patterson M: Spontaneous human lymphocyte mediated cytotoxicity against tumor target cells. IX. The quantitation of natural killer cell activity. J Clin Immunol 1: 51-63, 1981.
16. Mellstedt H, Frodin JE, Masucci G, Ragnhammar P, Fagerberg J, Shetye J, Wersall P, Osterborg A: The therapeutic use of monoclonal antibodies in colorectal carcinoma. SemOncol 18: 462-477, 1991.
17. Bucher M, Friess H, Muhrer KH: A randomized controlled trial of adjuvant immunotherapy (murine monoclonal antibody 494/32) in resectable pancreatic cancer. Cancer 68: 1507-1512, 1991.
18. Schneider-Gadicke E, Riethmuller G: Prevention of manifest metastasis with monoclonal antibodies; A novel approach to immunotherapy of solid tumors. Eur J Cancer 31: 1326-1246, 1995.
19. Saleh MN, Khzaeli MB, Wheeler RH, Bucy RP, Liu T, Everson MP, Munn DH, Schlom J, Lobuglio AF: Phase II trial of murine monoclonal antibody D612 combined with recombinant human monocyte colony stimulating factor (rhM-CSF) in patient with metastastic gastrointestinal cancer. Cancer Res 55: 4339-4346, 1995.